Xenitra signs $12M China distribution deal

·       Xenitra signed a three-year pharmaceutical procurement agreement worth at least $12 million with partner Kangsheng.

·       Following the announcement, the company's share price surged 50% to trade at $0.003.

·       The agreement expands Xenitra's distribution network for over-the-counter medicines across Chinese e-commerce platforms and retail pharmacies.

Xenitra (ASX:XEN) executed a three-year agreement with Kangsheng to deliver at least $12 million in pharmaceutical sales.

The commercial agreement follows Xenitra's recent acquisition of Hong Kong Fukang Trading to expand its distribution footprint.

The company stated that initial commercial orders under the deal will begin this quarter after operational onboarding completes.

Xenitra noted that Kangsheng generates over 900 million Chinese yuan in revenue across Chinese retail pharmacies and e-commerce platforms.

Following the announcement, the Xenitra share price was up 50% at $0.003.

Xenitra's broader growth strategy relies on three main pillars: over-the-counter pharmaceuticals, nutritionals, and a tokenised sales ecosystem.

The company's model integrates international healthcare brands into established Chinese digital storefronts and physical distribution channels.